Skip to main content

EU201

Alzheimer's

EU201

Leeftijd icoon
50 - 80 years (M / F)
Diagnose icoon
Diagnosis Mild Cognitive Impairment (MCI), Light Stage Alzheimer's
Duratie onderzoek
1,5 years
Locatie icoon
Amsterdam

About this research

In order to participate in this study, you must be able to speak and read Dutch fluently.

The research drug T-817MA is a new drug against Alzheimer’s disease. With this study, the researchers want to find out more about the safety and effectiveness of the drug.

You visit our research center every twelve weeks where you receive T-817MA tablets or placebo tablets. Half of the participants will receive the study drug and the other half the placebo. During a few visits, questionnaires will be done, blood tests and physical examinations will take place, and MRI scans and EEGs will be done. The period in which you receive the research drug is eighteen months.

This study is commissioned by Toyama.

This text has been directly translated from the Dutch trial description as approved by the Ethical Committee.

Screening – Selection

During three visits in a maximum period of six weeks, it will be determined whether you meet the study criteria and whether your health allows participation in the study. If so, you may participate in the study. The selection includes blood tests, physical examinations, memory tests, questionnaires, an MRI scan, an EEG, and a spinal tap.

Follow-up

After completing the treatment phase, participants will be followed for up to six weeks and will return to the center once for a final check-up. During this last check-up visit, questionnaires and tests will be done for your memory, among other things, a final blood test, physical examination, and a spinal tap will be performed.

A total of 14 visits were made to the research center over a period of 6 weeks (screening) and 48-96 weeks (treatment).

Who can participate?

  • You have a diagnosis of Mild Cognitive Impairment (MCI) or mild-stage Alzheimer’s disease
  • You are between 50-80 years old
  • Use of Alzheimer’s medication is permitted, provided it has been the same dose for more than three months.
  • You have a family carer who can accompany you during a few visits to the research center and answer questions about your health and functioning, among other things.

Take action against Alzheimer’s. Sign up to participate.

Latest Alzheimer’s trials

Filter

Alzheimer's

PRImus AD

The goal of this study is to evaluate how safe and effective the new drug PRI-002 is for the treatment of participants with MCI or a mild form of dementia caused by Alzheimer’s disease. The study compares the effect of the new drug PRI-002 with the effect of a placebo (a drug without an active ingredient, a 'fake drug'). The study drug is a capsule that is taken orally.

audience55 - 80 years

levelMCI or a mild form of dementia caused by Alzheimer’s disease

durationApproximately 1 to 2 years

locationAmsterdam, Den Bosch or Zwolle

Alzheimer's

Celia

The goal of this study is to evaluate how safe and effective the new drug BIIB080 is for the treatment of participants with mild to moderate Alzheimer’s disease. The study compares the effect of the new drug BIIB080 with the effect of a placebo (a drug without an active ingredient, a 'fake drug'). The study drug is injected into the back.

audience50 - 80 years

levelMild to moderate Alzheimer’s disease

durationApproximately 2 years

locationAmsterdam

Alzheimer's

IBC-01-01

The goal of this study is to evaluate how safe, tolerable and effective the new drug IBC-Ab002 is for the treatment of participants with early stage Alzheimer’s disease. The study compares the effect of the new drug IBC-Ab002 with the effect of a placebo (a drug without an active ingredient, a 'fake drug'). The study drug is administered through an intravenous (IV) injection.

audience50-80 years

levelEarly stage Alzheimer's disease

duration54 weeks

locationAmsterdam